The US Guaifenesin market continued to fall in the first half of November after the big drop in October. Prices softened further as global oversupply, origin market availability and US pharmaceutical demand were all low. Importers were cautious and delayed major bookings expecting deeper cuts. Exporters with inventory were cutting CFR offers aggressively to move stock. October’s 3.26% decline set the tone for November and with steady inflows from major producing regions US inventory was under pressure. Indian production under government backed capacity incentives was a big contributor to excess supply and shifting trade flows especially diverted shipments from US to China further unbalanced the supply demand equation. US formulators were selective in their buying for cough and cold formulations and were using existing inventory, so offtake was limited. Market expects prices to continue to fall if oversupply continues, and buyers are on wait and watch mode.
